Clinical Trial Search

Primary: Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8. — 2.9; -3.7; -10.6 percent change from baseline — p=0.1122

Primary: Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F) — 553; 543 L/hr

Primary: Percent Change From Baseline to Week 24 in LDL-C — -6.23; -44.53 percent change — p=< 0.0001

Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants

Primary: Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab — 238 Milligrams per Liter (mg/L)

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -27.70; -0.95 Percent Change — p=<0.001

Primary: Number of LDLR Gene Mutations — 7 gene mutations

Primary: LDL-Cholesterol (mg/dL) — 396.0; 481.4 mg/dL — p=0.005

Primary: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand — 9.7; -33.6; -4.4; -38.2 percent…

Primary: Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study — 6.304; 5.921; 4.087; 3.675 mMol/L

Primary: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline — -53.910; -56.529; -51.633 Percent change from Baseline…

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8 — -41.1; -7.9; -40.6; -49.8 percent change

Primary: The Number of Participants Who Experianced Adverse Events and Serious Adverse Events — 5 participants

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -49.45; -34.43 percent change — p=<0.01

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis — -4.1 percent change

Primary: Percent Change From Baseline in LDL-C — -37.86; -43.67; -42.88 Percentage change — p=<0.001

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.12; -42.70; -55.24 percent change — p=<0.001

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 36; 69; 7; 25 Participants

Primary: Number of Participants With Adverse Events — 94; 174; 76; 143 Participants

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.3; -54.2 percent change — p=<0.001

Primary: Percent Change From Baseline in LDL-C at Week 12 — -2.02; 5.53; -61.25; -55.74 percent change — p=<0.001

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period — -49.17 Percent Change

Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -27.14; 1.40 percent change in LDL-C — p=<.0001

Primary: Mean Percent Change in LDL-C From Baseline To Week 12 — -10.6; 8.2 percent change — p=<0.0001

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis — -10.7; -28.9; -31.5; -42.5 percent change — p=0.0000

Primary: Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -16.5 percent change

Primary: Serum Cholesterol to Total Sterol Ratio — 90.82; 93.99 percent total cholesterol — p=0.002

Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -21.6; 11.7 percent change in LDL-C

Primary: Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C). — 8.6; 8.6 units on a scale — p=1.0

Primary: Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1 — -27.17; -6.77; -22.96; -10.62 Percent